GDF-15 Biomarker Risk Stratification for Cardiac Intervention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic techniques for cardiovascular complications, particularly in emergency situations, are unreliable for accurate risk assessment and personalized treatment planning, often leading to insufficient or adverse treatment outcomes due to the lack of effective biomarkers for predicting cardiac interventions and mortality risks.

Innovation Solution

A method involving the determination of Growth-Differentiation Factor-15 (GDF-15) levels in a subject's sample, compared to a reference amount, to identify susceptibility to cardiac interventions and predict mortality or acute cardiovascular events, potentially combined with natriuretic peptide and cardiac troponin analysis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional diagnostic techniques (electrocardiographic and echocardiographic measurements, symptom analysis) are used for risk assessment, then the diagnostic process is simple and quick, but the reliability and accuracy of risk assessment is insufficient

Engineering Contradiction:

Improvereliability of risk assessmentVSAvoidcomplexity of diagnostic method

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces new measurement parameters (biomarker concentrations such as GDF-15, natriuretic peptides, and cardiac troponin) to transform the diagnostic approach from conventional physiological measurements to molecular concentration analysis, thereby improving reliability of risk assessment

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses biomarkers as intermediary substances that mediate between the physiological state and the diagnostic measurement, allowing indirect but more reliable assessment of cardiovascular risk through blood sample analysis

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If conventional biomarkers (cardiac troponin, natriuretic peptides) are used alone for diagnosis, then the diagnostic method is straightforward, but the accuracy for personalized treatment planning is insufficient

Engineering Contradiction:

Improveaccuracy of risk predictionVSAvoidcomplexity of biomarker analysis

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent combines multiple biomarker measurements (GDF-15, natriuretic peptides, and cardiac troponin) into a single diagnostic approach, merging their individual predictive capabilities to achieve higher overall accuracy in risk assessment and personalized treatment planning

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS11199552B2Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof

Publication Date: 2021.12.14 MEDIZINISCHE HOCHSCHULE HANNOVER

AI summary

The present invention relates to a method of identifying a subject being susceptible to a cardiac intervention based on the determination of GDF-15 in a sample of a subject in need of a cardiac intervention. Moreover, the present invention pertains to a method for predicting the risk of mortality or a further acute cardiovascular event for a subject suffering from a cardiovascular complication based on the determination of GDF-15 and a natriuretic peptide and/or a cardiac troponin in a sample the said subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.